Glucagon-like peptide 1-based drugs and pancreatic safety--reply
JAMA Intern Med
.
2013 Oct 28;173(19):1843-4.
doi: 10.1001/jamainternmed.2013.8128.
Author
Sonal Singh
1
Affiliation
1
Department of Medicine and the Center for Public Health and Human Rights, Johns Hopkins University Schools of Medicine and Public Health, Baltimore, Maryland.
PMID:
24165846
DOI:
10.1001/jamainternmed.2013.8128
No abstract available
Publication types
Letter
Comment
MeSH terms
Diabetes Mellitus, Type 2 / complications*
Female
Glucagon-Like Peptide 1 / adverse effects*
Hospitalization*
Humans
Male
Pancreatitis / chemically induced*
Substances
Glucagon-Like Peptide 1